Antihypertensive drugs Risuvastatin Calcium is an anti-hyperlipidemia drug, HMG-CoA reductase inhibitor, developed by the British AstraZeneca successful, for the treatment of a variety of lipid abnormalities, including high cholesterol Disorders, mixed lipid disorders and simple hypertriglyceridemia. Rosuvastatin calcium is currently the most comprehensive lipid-lowering drugs listed in the lipid-lowering effect, the most comprehensive effect of lipid-lowering statins, than the world's most effective treatment of atorvastatin has a better reduction of low-density lipoprotein cholesterol and Improve the role of high-density lipoprotein, and have better tolerance, lower side effects and unique pharmacokinetic characteristics, half-life of about 20h, just take once a day.

Pharmacological effects rosuvastatin is a selective HMG-CoA reductase inhibitor. HMG-CoA reductase inhibitor is a rate-limiting enzyme that transitions 3-hydroxy-3-methylglutaryl coenzyme A to the precursor of pivalate-cholesterol. The main site of action of rosuvastatin is the liver-lowering target of cholesterol. Rosuvastatin increases the number of surface receptors in liver LDL cells, promotes absorption and catabolism of LDL, inhibits hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.

Chinese name: rosuvastatin calcium

(3R, 5S, 6E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- (N- (4-fluorophenyl) -6-isopropylidene- Methyl-N-methanesulfonamido) -5-pyrimidine] -3,5-dihydroxy-6-heptenoate; superstarch calcium; rosuvastatin calcium; rosuvastatin calcium; rosuvastatin calcium

English name: Rosuvastatin calcium

(3R, 5S, 6E) -7- [4- (4-fluorophenyl) -6- (1-methylethyl) -2- [N-methyl (R) (R) (4-Fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) -3-hydroxy-6-Heptenoic calcium; RosuvastatinCalcium & Z7, Z8, R3; ) Amino] pyrimidin-5-yl} -3,5-dihydroxyhept-6-enoic acid; Rosuvastatin Calium

CAS Number: 147098-20-2

Molecular formula: C44H54CaF2N6O12S2

Molecular weight: 1001.14

Antihypertensive drugs Risuvastatin Calcium is an anti-hyperlipidemia drug, HMG-CoA reductase inhibitor, developed by the British AstraZeneca successful, for the treatment of a variety of lipid abnormalities, including high cholesterol Disorders, mixed lipid disorders and simple hypertriglyceridemia. Rosuvastatin calcium is currently the most comprehensive lipid-lowering drugs listed in the lipid-lowering effect, the most comprehensive effect of lipid-lowering statins, than the world's most effective treatment of atorvastatin has a better reduction of low-density lipoprotein cholesterol and Improve the role of high-density lipoprotein, and have better tolerance, lower side effects and unique pharmacokinetic characteristics, half-life of about 20h, just take once a day.

Pharmacological effects rosuvastatin is a selective HMG-CoA reductase inhibitor. HMG-CoA reductase inhibitor is a rate-limiting enzyme that transitions 3-hydroxy-3-methylglutaryl coenzyme A to the precursor of pivalate-cholesterol. The main site of action of rosuvastatin is the liver-lowering target of cholesterol. Rosuvastatin increases the number of surface receptors in liver LDL cells, promotes absorption and catabolism of LDL, inhibits hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.

For patients with homozygous and heterozygous familial hypercholesterolemia, non-familial hypercholesterolemia and mixed dyslipidemia patients, rosuvastatin reduced total cholesterol, LDL-C, ApoB, and non-HDL-C levels. Rosuvastatin also reduced TG and increased HDL-C levels. For patients with hypertriglyceridemia alone, rosuvastatin reduced total cholesterol, LDL-C, VLDL-C, ApoB, non-HDL-C, TG levels and increased HDL-C levels.

2. Vitamin K antagonists: As with other HMG-CoA reductase inhibitors, the use of this product or the gradual increase in the dose of vitamin K antagonists (such as warfarin) may lead to INR (International Standardization Ratio) increased. Disabling this product or decreasing the dosage of this product can result in reduced INR. In this case, proper detection of INR is required.

3. The combination of nicotine, fenofibrate, other fibrates and lipid-lowering doses (≥1g / day) with HMG-CoA reductase inhibitors increases the risk of myopathy, which may be due to They can cause myopathy when administered alone.

4. Antacids

Use for the manufacture of hypoglycemic agents

 

KG content of 99% powder white 1 kg / 1 kg